Lynch Karen S
SEC CIK 1333760 · EDGAR
BoughtSold
Most active insiders at TMO, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | CASPER MARC N | COB, CEO, Dir | — | $53.89M |
| 2 | Lagarde Michel | EVP, COO | — | $51.31M |
| 3 | Shafer Michael D | EVP | — | $22.54M |
| 4 | Britt Lisa P. | SVP, Chief HR Off | — | $16.87M |
| 5 | Lowery Frederick M. | EVP | — | $8.15M |
| 6 | Pettiti Gianluca | Pres, COO | — | $5.12M |
| 7 | Holmes Joseph R. | VP, CAO | — | $245.6K |
| 8 | Meyer James | CFO, Sr. VP | — | — |
| 9 | Shropshire Thomas B Jr. | SVP, GC | — | — |
| 10 | Keith R. Alexandra | Dir | — | — |
| 16 | Lynch Karen S | Dir | — | — |
Transactions 13
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-22 16:12 | 2026-05-20 | TMO | Thermo Fisher Scientific | Lynch Karen S | Dir | A - Grant | $0.00 | +499 | 1,159 | +76% | $0 | |
| 2025-11-14 | 2025-11-12 | ADP | Automatic Data Processing | Lynch Karen S | Dir | A - Grant | $0.00 | +1,453 | 1,535 | +1,772% | $0 | |
| 2025-05-22 | 2025-05-21 | TMO | Thermo Fisher Scientific | Lynch Karen S | Dir | A - Grant | $0.00 | +565 | 660 | +595% | $0 | |
| 2025-02-21 | 2025-02-19 | TMO | Thermo Fisher Scientific | Lynch Karen S | Dir | A - Grant | $0.00 | +95 | 95 | New | $0 | |
| D | 2024-04-03 | 2024-04-01 | CVS | CVS Health | Lynch Karen S | Pres, CEO, Dir | F - Tax | $79.56 | -62.0K | 74.7K | -45% | -$4.93M |
| D | 2024-04-03 | 2024-04-01 | CVS | CVS Health | Lynch Karen S | Pres, CEO, Dir | A - Grant | $79.56 | +45.2K | 45.2K | New | +$3.60M |
| 2024-02-14 | 2024-02-12 | CVS | CVS Health | Lynch Karen S | Pres, CEO, Dir | A - Grant | $0.00 | +136.6K | 136.6K | New | $0 | |
| 2023-05-05 | 2023-05-03 | CVS | CVS Health | Lynch Karen S | Pres, CEO, Dir | P - Purchase | $69.75 | +14.0K | 431.4K | +3% | +$976.5K | |
| D | 2023-04-04 | 2023-04-01 | CVS | CVS Health | Lynch Karen S | Pres, CEO, Dir | F - Tax | $74.31 | -93.7K | 112.9K | -45% | -$6.96M |
| 2023-02-03 | 2023-02-02 | CVS | CVS Health | Lynch Karen S | Pres, CEO, Dir | A - Grant | $0.00 | +206.6K | 206.6K | New | $0 | |
| D | 2022-04-05 | 2022-04-01 | CVS | CVS Health | Lynch Karen S | Pres, CEO, Dir | F - Tax | $101.09 | -116.9K | 210.1K | -36% | -$11.82M |
| 2022-02-23 | 2022-02-21 | CVS | CVS Health | Lynch Karen S | Pres, CEO, Dir | A - Grant | $0.00 | +257.9K | 327.0K | +373% | $0 | |
| 2021-12-01 | 2021-11-28 | CVS | CVS Health | Lynch Karen S | Pres, CEO, Dir | F - Tax | $91.52 | -14.1K | 69.1K | -17% | -$1.29M |
Purchase Sale Sale after option exercise All abbreviations